Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of Prompt Proton Emission in N=Z-1 ^{61}Ga: Isospin Symmetry at the Limit of Nuclear Binding.

Physical review letters·2025
Same author

Deformation and Collectivity in Doubly Magic ^{208}Pb.

Physical review letters·2025
Same author

Improved Tensor Current Limit from ^{8}B β Decay Including New Recoil-Order Calculations.

Physical review letters·2024
Same author

Direct Determination of Fission-Barrier Heights Using Light-Ion Transfer in Inverse Kinematics.

Physical review letters·2023
Same author

Quenching of Single-Particle Strength in A=15 Nuclei.

Physical review letters·2022
Same author

Search for Nova Presolar Grains: γ-Ray Spectroscopy of ^{34}Ar and its Relevance for the Astrophysical ^{33}Cl(p,γ) Reaction.

Physical review letters·2020
Same journal

Unhealthy fat distribution as a sex-specific predictor of declining hippocampus insulin sensitivity.

Diabetologia·2026
Same journal

Baseline and longitudinal joint associations of alcohol consumption and obesity with diabetes risk: evaluating multiplicative and additive interactions.

Diabetologia·2026
Same journal

GIP contributes to postprandial regulation of splanchnic blood supply in humans with type 2 diabetes: a randomised, single-blinded, placebo-controlled, crossover study.

Diabetologia·2026
Same journal

Correction: Analysis of glycaemic control with a connected smart pen cap in adults with type 1 diabetes: a randomised, open-label, parallel-group trial.

Diabetologia·2026
Same journal

History of infertility, risk of type 2 diabetes and HbA<sub>1c</sub> levels in the Nurses' Health Study II.

Diabetologia·2026
Same journal

Delayed maturation of the milk microbiome in women with type 1 diabetes.

Diabetologia·2026
See all related articles

Related Experiment Video

Updated: Jul 2, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Mitochondrial dysfunction and delayed hepatotoxicity: another lesson from troglitazone.

N L Julie1, I M Julie, A I Kende

  • 1Department of Pathology, Shady Grove Adventist Hospital, Rockville, MD, USA. neilljulie@aol.com

Diabetologia
|August 30, 2008
PubMed
Summary
This summary is machine-generated.

Troglitazone caused severe liver injury, with seven of eleven patients developing long-term cirrhosis. Mitochondrial toxicity is identified as a key mechanism, suggesting potential predictability for drug-induced liver injury.

More Related Videos

Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides
08:39

Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides

Published on: September 16, 2020

Related Experiment Videos

Last Updated: Jul 2, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides
08:39

Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides

Published on: September 16, 2020

Area of Science:

  • Hepatology
  • Pharmacology
  • Toxicology

Background:

  • Troglitazone, a type 2 diabetes drug, was withdrawn globally due to severe drug-induced liver injury (DILI).
  • Long-term consequences and precise toxicity mechanisms of troglitazone remain incompletely understood.
  • Distinguishing troglitazone-specific toxicity from class effects of thiazolidinediones (TZDs) is crucial.

Purpose of the Study:

  • To investigate the long-term outcomes of liver injury in patients treated with troglitazone.
  • To elucidate the underlying mechanisms of troglitazone-induced liver injury.
  • To assess the potential for mitochondrial toxicity as a contributing factor.

Main Methods:

  • A case series of eleven patients with type 2 diabetes mellitus treated with troglitazone (1997-2000).
  • Exhaustive review of patient medical records and long-term outcome data for non-fatal cases.
  • Comprehensive literature review and analysis of experimental troglitazone toxicity data.

Main Results:

  • Seven of eleven patients experienced long-term liver injury, with some progressing to cirrhosis.
  • All cases exhibited liver injury patterns consistent with troglitazone toxicity.
  • Mitochondrial toxicity was identified as a central mechanism in troglitazone-induced liver injury.

Conclusions:

  • Troglitazone-induced liver injury can have severe long-term consequences, including cirrhosis.
  • Mitochondrial toxicity plays a significant role and may be a key factor in predicting DILI.
  • Considering mitochondrial toxicity in cases of delayed DILI can aid in early risk assessment and prevention.